Feligen RCP

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Pieejams no:

Virbac

ATĶ kods:

QI06AD04

SNN (starptautisko nepatentēto nosaukumu):

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Zāļu forma:

Powder for solution for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Cats

Ārstniecības joma:

Live Viral Vaccine

Autorizācija statuss:

Authorized

Autorizācija datums:

2005-10-28

Produkta apraksts

Revised: February 2018
AN: 00438/2017
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Feligen
®
RCP
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1
2.2
FREEZE-DRIED COMPONENT
- Live feline calicivirosis (strain F9) ……………………..
- Live feline viral-rhinotracheitis virus (strain F2) ……...
- Live feline viral-panleucopenia virus (strain LR 72) …
DILUENT
Water for injection …………………………………...
formula and titre per dose
10
4.6
- 10
6.1
TCID
50
10
5.0
-
10
6.6
TCID
50
10
3.7
- 10
4.5
TCID
50
1 ml
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection after reconstitution of the freeze-dried
component in the diluent.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The vaccine is intended for the active immunisation of healthy cats of
minimum 9 weeks
of age against:
-
feline calicivirosis and feline viral rhinotracheitis to reduce
clinical signs and viral
excretion;
-
feline panleucopenia to prevent leucopenia and to reduce clinical
signs.
Onset of immunity is established four weeks after vaccination for
calici virus and
rhinotracheitis and three weeks for panleucopenia virus. This immunity
lasts for 12
months.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
High level of maternal antibodies can interfere with the response to
vaccination.
Maternally derived antibodies, especially those against feline
panleucopenia virus, can
negatively influence the immune response to vaccination.
Revised: February 2018
AN: 00438/2017
Page 2 of 4
4.5
SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN
BY THE
PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS
i.
Special precautions for use in animals
Vaccinate only healthy animals.
ii.
Special precautions for the person administering the veterinary
medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately
and
show the packa